Overview

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Penicillanic Acid
Piperacillin
Piperacillin, Tazobactam Drug Combination
Tazobactam
Criteria
Inclusion Criteria:

- Eligible patients of either sex, 15 years of age or older

- Patients who are admitted to the department of hematology and oncology

- Provide written informed consent

Exclusion Criteria:

- Patients who have hypersensitivity to β-lactam antibiotics

- Female who are pregnant or breast-feeding

- Any underlying conditions or non-infectious diseases that will be ultimately fatal
within 30 days